Novartis Announces $84M Deal with Geneva Proteomics | GenomeWeb

NEW YORK, Oct. 17 – Swiss pharmaceutical giant Novartis has agreed to pay Geneva Proteomics $84 million to analyze the proteomes of three types of human tissues over the next five years, the companies announced Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.